Treadwell Therapeutics
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $27.0m | Seed | |
* | $91.0m | Series B | |
Total Funding | €107m |
Related Content
Recent News about Treadwell Therapeutics
EditTreadwell Therapeutics is a clinical-stage oncology company that operates in the healthcare sector, specifically in the field of cancer treatment. The company is dedicated to developing innovative therapies for cancer, focusing on novel targets that have not been extensively explored in the past. Treadwell serves a market of patients who have limited treatment options, aiming to provide them with new, potentially life-changing solutions.
The company operates on a business model that involves the complete drug discovery and development process, all under one roof. This means that Treadwell is involved in every step of the process, from the initial concept and scientific research to the clinical trials and beyond. This approach allows the company to maintain control over the quality and direction of its research and development, potentially leading to more effective and innovative treatments.
Treadwell's revenue is generated primarily through the development and commercialization of its therapies. As the company advances its clinical candidates and brings them to market, it stands to earn income from the sales of these treatments. Additionally, the company may also generate revenue through partnerships with other healthcare companies or through grants and funding for its research.
In summary, Treadwell Therapeutics is a pioneering oncology company that aims to break new ground in cancer treatment. It serves a market of patients with limited options, using its in-house drug discovery and development engine to create innovative therapies.
Keywords: Oncology, Cancer Treatment, Drug Discovery, Drug Development, Clinical Stage, Novel Targets, Therapeutic Intervention, Biologics, T-cell Receptor-Based Cell Therapy, First-in-Class Pipeline.